Levonorgestrel and ethinylestradiol

PreclinicalSmall molecule

Levonorgestrel and ethinylestradiol is one of 3 small molecule programs targeting GnRH Antagonist. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gnrh AntagonistCompleted

Gnrh AntagonistPreclinical

Completed

Competition

Competitive Landscape

2 competitors in Gnrh Antagonist

#DrugCompanyPhaseTrials

Estrasorb

Novo Nordisk

Preclinical

1 2

Duphaston

Merck & Co.

Preclinical

3 3

Levonorgestrel and ethinylestradiol

IIVI Madrid

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Oral1 trial

Oral Estradiol Valerate Versus Oral Contraceptive Pill in Invitro Fertilization Patients

Completed·IIVI Madrid·Phase 4·NCT01501448·118 enrolled

GnRH Antagonist1 trial

Oral Contraceptive Pill and GnRH Antagonist Versus Long Protocol in IVF Patients

Completed·IIVI Madrid·N/A·NCT01157754·115 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Levonorgestrel and ethinylestradiol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Levonorgestrel and ethinylestradiol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Levonorgestrel and ethinylestradiol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — IVI Madrid company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IIVI Madrid

Levonorgestrel and ethinylestradiol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Oral1 trial

GnRH Antagonist1 trial

References

Drug Info

Quick Facts

Related News